PT3077004T - Novo tratamento de combinação para a leucemia mieloide aguda (lma) - Google Patents
Novo tratamento de combinação para a leucemia mieloide aguda (lma)Info
- Publication number
- PT3077004T PT3077004T PT148089113T PT14808911T PT3077004T PT 3077004 T PT3077004 T PT 3077004T PT 148089113 T PT148089113 T PT 148089113T PT 14808911 T PT14808911 T PT 14808911T PT 3077004 T PT3077004 T PT 3077004T
- Authority
- PT
- Portugal
- Prior art keywords
- aml
- myeloid leukemia
- acute myeloid
- combination treatment
- novel combination
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 238000011284 combination treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361912152P | 2013-12-05 | 2013-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3077004T true PT3077004T (pt) | 2020-04-16 |
Family
ID=52014047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT148089113T PT3077004T (pt) | 2013-12-05 | 2014-12-01 | Novo tratamento de combinação para a leucemia mieloide aguda (lma) |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US20160303158A1 (pt) |
| EP (1) | EP3077004B1 (pt) |
| JP (3) | JP6297695B2 (pt) |
| KR (1) | KR101862955B1 (pt) |
| CN (1) | CN105792847B (pt) |
| AR (1) | AR098576A1 (pt) |
| AU (1) | AU2014359422B2 (pt) |
| BR (1) | BR112016009669B1 (pt) |
| CA (1) | CA2926307C (pt) |
| CL (1) | CL2016001345A1 (pt) |
| CR (1) | CR20160173A (pt) |
| DK (1) | DK3077004T3 (pt) |
| EA (1) | EA201690785A1 (pt) |
| ES (1) | ES2785203T3 (pt) |
| HK (1) | HK1222808A1 (pt) |
| HR (1) | HRP20200566T1 (pt) |
| HU (1) | HUE049434T2 (pt) |
| IL (1) | IL244888B (pt) |
| LT (1) | LT3077004T (pt) |
| MA (1) | MA39040A1 (pt) |
| MX (1) | MX370618B (pt) |
| PE (1) | PE20160591A1 (pt) |
| PH (1) | PH12016500933A1 (pt) |
| PL (1) | PL3077004T3 (pt) |
| PT (1) | PT3077004T (pt) |
| RS (1) | RS60142B1 (pt) |
| SG (1) | SG11201604504VA (pt) |
| SI (1) | SI3077004T1 (pt) |
| TW (2) | TWI627954B (pt) |
| WO (1) | WO2015082384A1 (pt) |
| ZA (1) | ZA201602829B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101623985B1 (ko) | 2007-03-28 | 2016-05-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| JP2013535514A (ja) | 2010-08-13 | 2013-09-12 | エイルロン セラピューティクス，インコーポレイテッド | ペプチド模倣大環状分子 |
| JP6342808B2 (ja) | 2011-10-18 | 2018-06-13 | エイルロン セラピューティクス，インコーポレイテッド | ペプチドミメティック大環状化合物 |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| SG11201604504VA (en) * | 2013-12-05 | 2016-07-28 | Hoffmann La Roche | Novel combination treatment for acute myeloid leukemia (aml) |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| CN107106642B (zh) | 2014-09-24 | 2021-02-26 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| KR20180043835A (ko) * | 2015-09-03 | 2018-04-30 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 매크로사이클 및 이의 용도 |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| CN109414436A (zh) | 2016-06-06 | 2019-03-01 | 细胞基因公司 | 用2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺治疗血液恶性肿瘤 |
| US10471154B2 (en) * | 2016-08-08 | 2019-11-12 | Fei Xiao | Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof |
| PL3541387T3 (pl) | 2016-11-15 | 2021-10-25 | Novartis Ag | Dawka i schemat dla inhibitorów interakcji hdm2-p53 |
| JP6617208B2 (ja) * | 2017-03-31 | 2019-12-11 | ノバルティス アーゲー | 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン |
| US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3858361A4 (en) | 2018-09-28 | 2021-12-01 | FUJIFILM Corporation | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR ACTIVATOR USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE |
| TW202118488A (zh) * | 2019-07-26 | 2021-05-16 | 大陸商蘇州亞盛藥業有限公司 | Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途 |
| JP2024519335A (ja) * | 2021-05-13 | 2024-05-10 | ンカルタ・インコーポレイテッド | がん免疫療法のための投薬レジメン |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1503757B1 (en) * | 2002-05-02 | 2007-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DE102005012681A1 (de) * | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | Neue 1,5-Dihydro-pyrrol-2-one |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| CN101773408B (zh) * | 2010-01-15 | 2012-04-04 | 平荧 | 多功能排针结合电凝固技术提升下垂皮肤的装置 |
| WO2011127058A2 (en) * | 2010-04-09 | 2011-10-13 | The Regents Of The University Of Michigan | Biomarkers for mdm2 inhibitors for use in treating disease |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| SG11201604504VA (en) * | 2013-12-05 | 2016-07-28 | Hoffmann La Roche | Novel combination treatment for acute myeloid leukemia (aml) |
| US9657351B2 (en) * | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
-
2014
- 2014-12-01 SG SG11201604504VA patent/SG11201604504VA/en unknown
- 2014-12-01 RS RS20200394A patent/RS60142B1/sr unknown
- 2014-12-01 HU HUE14808911A patent/HUE049434T2/hu unknown
- 2014-12-01 PE PE2016000615A patent/PE20160591A1/es not_active Application Discontinuation
- 2014-12-01 PL PL14808911T patent/PL3077004T3/pl unknown
- 2014-12-01 JP JP2016536634A patent/JP6297695B2/ja active Active
- 2014-12-01 LT LTEP14808911.3T patent/LT3077004T/lt unknown
- 2014-12-01 MX MX2016007170A patent/MX370618B/es active IP Right Grant
- 2014-12-01 PT PT148089113T patent/PT3077004T/pt unknown
- 2014-12-01 SI SI201431551T patent/SI3077004T1/sl unknown
- 2014-12-01 WO PCT/EP2014/076063 patent/WO2015082384A1/en active Application Filing
- 2014-12-01 EA EA201690785A patent/EA201690785A1/ru unknown
- 2014-12-01 AR ARP140104469A patent/AR098576A1/es unknown
- 2014-12-01 ES ES14808911T patent/ES2785203T3/es active Active
- 2014-12-01 CA CA2926307A patent/CA2926307C/en active Active
- 2014-12-01 US US15/101,258 patent/US20160303158A1/en not_active Abandoned
- 2014-12-01 AU AU2014359422A patent/AU2014359422B2/en active Active
- 2014-12-01 EP EP14808911.3A patent/EP3077004B1/en active Active
- 2014-12-01 DK DK14808911.3T patent/DK3077004T3/da active
- 2014-12-01 KR KR1020167014756A patent/KR101862955B1/ko active IP Right Grant
- 2014-12-01 BR BR112016009669-0A patent/BR112016009669B1/pt active IP Right Grant
- 2014-12-01 CN CN201480066531.9A patent/CN105792847B/zh active Active
- 2014-12-03 TW TW103142020A patent/TWI627954B/zh active
- 2014-12-03 TW TW107105068A patent/TWI678204B/zh active
- 2014-12-04 US US14/560,086 patent/US9956243B2/en active Active
-
2016
- 2016-04-04 IL IL244888A patent/IL244888B/en active IP Right Grant
- 2016-04-14 CR CR20160173A patent/CR20160173A/es unknown
- 2016-04-25 ZA ZA2016/02829A patent/ZA201602829B/en unknown
- 2016-05-17 MA MA39040A patent/MA39040A1/fr unknown
- 2016-05-19 PH PH12016500933A patent/PH12016500933A1/en unknown
- 2016-06-02 CL CL2016001345A patent/CL2016001345A1/es unknown
- 2016-09-22 HK HK16111115.9A patent/HK1222808A1/zh unknown
-
2018
- 2018-02-21 JP JP2018028482A patent/JP6918724B2/ja active Active
-
2020
- 2020-02-19 US US16/794,991 patent/US20200253999A1/en not_active Abandoned
- 2020-04-07 HR HRP20200566TT patent/HRP20200566T1/hr unknown
-
2021
- 2021-02-05 JP JP2021017415A patent/JP2021091690A/ja active Pending
- 2021-05-19 US US17/324,248 patent/US20220031726A1/en not_active Abandoned
-
2023
- 2023-04-03 US US18/130,016 patent/US20230381215A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222808A1 (zh) | 急性骨髓性白血病 的新型組合治療 | |
| HK1204578A1 (en) | Medicament for the treatment of acute myeloid leukemia (aml) (aml) | |
| HK1216821A1 (zh) | 播種裝置 | |
| HK1215790A1 (zh) | 治療骨髓性白血病的方法 | |
| GB2513643B (en) | Medical accessory holder | |
| GB2515154B8 (en) | Drawer apparatus | |
| PT2956347T (pt) | Mesa de passageiro | |
| HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
| PL2777671T3 (pl) | Stół dla pacjenta | |
| GB201304872D0 (en) | Treatment | |
| EP2971608A4 (en) | PARTITION SHIELD | |
| AP2015008863A0 (en) | Seeding machine | |
| HK1216391A1 (zh) | 組合治療 | |
| EP2990056A4 (en) | ANTITUMOR AGENT | |
| EP2963676A4 (en) | SUSCEPTOR | |
| HK1222582A1 (zh) | 用於改善膀胱尿道協同失調的藥劑 | |
| GB201307310D0 (en) | Treatment | |
| PT2832260T (pt) | Mesa | |
| GB201320656D0 (en) | Pat table | |
| GB201321531D0 (en) | Treatment for cancers | |
| AU352793S (en) | Console table | |
| AU352794S (en) | Console table | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
| GB201321115D0 (en) | Treatment | |
| GB201300546D0 (en) | Cancer Treatment |